TGFB1 and breast cancer: Loss of CXADR, which is detected during malignant progression of breast cancer and other tumors of epithelial origin, leads to hyper-activation of AKT, inhibition of GSK-3β, increased activation of SNAIL and TWIST and more pronounced EMT in response to TGF-β1 [9].